A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer

NCT04340193 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer, Hepatocellular

Interventions

DRUG: nivolumab
DRUG: ipilimumab
PROCEDURE: TACE

Sponsor

Bristol-Myers Squibb